"Reporting of mild to moderate neuropsychiatric side effects, primarily anxiety, irritability, and sleep disturbances, was more frequent and dose-dependent with monlunabant compared to placebo," the Danish pharmaceutical giant conceded in a press release.
Though the drugs' areas of operations are different, some of their side effects are similar. Of the 243 people who took daily injections during the phase 2 monlunabant trial, the most common effects of the drugs were gastrointestinal.
While Novo says that none of these side effects were "serious," Fierce Pharma notes that the reported instances of psychiatric events is reminiscent of an earlier CB1 drug called Acomplia that was pulled from European markets after only two years because it too was associated with mental health issues.
[
Collection
]
[
|
...
]